Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.66 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377531 | 1.00 | PPARG (0.66) | PPARGPPARAPPARD | |
| SCHEMBL4609088 | 0.89 | PPARG (0.65) | PPARGPPARAPPARD | |
| Trifluoroacetic Acid SCHEMBL7711566 | 0.86 | PPARG (0.50) | PPARGPPARA | |
| SCHEMBL3909702 | 0.85 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL2786491 | 0.84 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL7922719 | 0.83 | PPARG (0.48) | PPARGPPARA | |
| Trifluoroacetic Acid SCHEMBL7705739 | 0.80 | PPARG (0.43) | PPARGPPARA | |
| SCHEMBL7920692 | 0.79 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL30475600 | 0.79 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL389037 | 0.79 | PPARG (1.00) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171692-A1 | Modulation of bone formation | ANDREW SCUTT (GB) | 2004-09-02 | — | — | US | claimed |
| JP-2003522787-A | — | — | 2003-07-29 | — | — | JP | claimed |
| US-20030139372-A1 | Modulation of bone formation | UNIVERSITY OF SHEFFIELD (GB) | 2003-07-24 | — | — | US | claimed |
| EP-1259233-A1 | MODULATION OF BONE FORMATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2002-11-27 | — | — | EP | claimed |
| WO-2001060355-A1 | MODULATION OF BONE FORMATION | UNIVERSITY OF SHEFFIELD (GB) | 2001-08-23 | — | — | WO | claimed |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (DE) | 2017-10-26 | — | — | US | disclosed |
| US-9724322-B2 | 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-08 | — | — | US | disclosed |
| US-20160199342-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| EP-2243766-B1 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| US-9034852-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-05-19 | — | — | US | disclosed |
| US-20030139372-A1 | Modulation of bone formation | UNIVERSITY OF SHEFFIELD (GB) | 2003-07-24 | — | — | US | disclosed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | ORTHO-MCNEIL PHARMACEUITCAL, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1259233-A1 | MODULATION OF BONE FORMATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002080936-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001060355-A1 | MODULATION OF BONE FORMATION | UNIVERSITY OF SHEFFIELD (GB) | 2001-08-23 | — | — | WO | disclosed |
| US-6166049-A | Use of an antagonist of PPARα and PPARγ for the treatment of syndrome X | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | GPR119, SLC2A4, SLC2A1 | PPARG 111/4885PPARA 410/4885PPARD 272/4885 |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | GPR119, SLC2A4, PPARG | PPARG 3/4885PPARA 12/4885PPARD 9/4885 |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
| US-20160199342-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.